Newsfeeds Archive - Page 10 of 461

2 minute read

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile

May 31, 2:25 PM

Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.

IONS

2 minute read

FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies

By Vandana Singh

May 31, 2:14 PM

FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.

BMY

2 minute read

Novartis Sues to Block Maryland’s New Drug Discount Law

By Vandana Singh

May 31, 2:12 PM

Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharmacies contracting with hospitals and clinics.

NVS

2 minute read

Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes

By Vandana Singh

May 31, 2:08 PM

Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products.

LLY

2 minute read

Pfizer Highlights ‘Unprecedented’ 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer

By Vandana Singh

May 31, 2:02 PM

Pfizer's Phase 3 CROWN trial results show Lorbrena significantly outperforms Xalkori in treating ALK-positive advanced NSCLC.

PFE

2 minute read

Moderna’s Scores FDA Approval For Its Second Product – Respiratory Syncytial Virus Vaccine

By Vandana Singh

May 31, 1:16 PM

FDA approves Moderna's mRESVIA (mRNA-1345), an mRNA vaccine for RSV, for adults 60+. The second approved mRNA product from Moderna.

MRNA

2 minute read

Novartis’ Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety

By Vandana Singh

May 31, 11:02 AM

Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, showing significant symptom improvement and a favorable safety profile up to Week 52.

NVS

2 minute read

Europe Approves Biogen’s Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder

By Vandana Singh

May 31, 10:25 AM

The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.

BIIB

1 minute read

Summit Therapeutics’ Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck’s Multi-Billion Keytruda In China Study

By Vandana Singh

May 31, 10:21 AM

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly improved progression-free survival in NSCLC patients compared to Keytruda.

MRK

2 minute read

Gilead’s Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer

By Vandana Singh

May 31, 9:27 AM

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed numerical improvements favoring Trodelvy.

GILD